SoftOx Solutions AS (SoftOx), a clinical-stage bio pharmaceutical company based
in Norway, announces that it has published its Annual Report for 2023. The Board
of Directors has approved the 2023 annual financial statements prepared in
accordance with the Norwegian Accounting Act and accounting standards and
practices generally accepted in Norway.These documents are also available at the
Company's website, https://soft-ox.com/press-releases-updates/. 

For further information, please contact: 
Geir Almås, CEO of SoftOx Solutions AS, or Ingrid Juven, COO at SoftOx Solutions
AS 
Mail: ir@soft-ox.com Phone: Front Desk: (+47) 948-59-599 
About SoftOx Solutions AS SoftOx Solutions AS (SoftOx, listed on Euronext Growth
Oslo) is a Norwegian medtech/biotech company based in Oslo with the aim of
helping to combat major threats to human health, namely the emergence of
antimicrobial resistance (AMR), biofilm infections in chronic wounds and the
spread of viruses. For more information on SoftOx, visit www.soft-ox.com